MKO Melt

Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) announced Tuesday its non-opioid, non-IV sedation formulation, MKO Melt, secured a patent for anesthesiological applications. The product, which has been dispensed more than 70,000 times since debuting in 2015, is expected to see a market-share swell from...

Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) owns, markets and dispenses a portfolio of compounded therapeutic in various areas, including ophthalmology, urology, otolaryngology and infectious diseases. Benzinga had the privilege of chatting with the company's CEO, Mark Baum, about its most recent...